Latest Mesothelioma Immunotherapy Combination Looks Promising

Scientists at the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital have uncovered a novel, two-agent immunotherapy combination that worked surprisingly well in animal models with malignant mesothelioma. The discovery has sparked new optimism for immunotherapy, which has struggled to provide consistently positive results with aggressive cancers such as mesothelioma. “This is the beginning of a new story of hope, a new combination of immunotherapy,” Dr. Mark Poznansky, director of the VIC and associate professor at Harvard Medical School, told Asbestos.com. “It worked quite well in aggressive mouse models. It looks promising for humans.” The combination involves AMD3100 (plerixafor) — an immune modulator that already has approval from the U.S. Food and Drug Administration (FDA) — and VIC-008, an investigational drug that targets a particular protein expressed in mesothelioma. “One [AMD3100] opens the gate to the immune system, breaks the barrier against immunity the tumor deploys. Then the other [VIC-008] activates the troops to go in and kill the tumor cells,” Poznansky said. “A double hit that is needed. Some cancers, especially mesothelioma, have so many ways to evade the immune system, you have to line up combinations that work together.” Immunotherapy Is Future of Cancer Care Cancer Immunology Research published the findings April 6. This combination also is being tested with ovarian cancer...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news

Related Links:

Shares in Boston Scientific (NYSE:BSX) rose slightly this morning after the company reported preliminary results for the fourth quarter and full year of 2018 that were in-line with estimates on Wall Street. The Marlborough, Mass.-based company said it expects to report $2.56 billion in sales for the fourth quarter and $9.82 billion for the full year. In Q4, Boston Scientific’s cardiovascular business pulled in $970 million in sales, while its rhythm &neuro unit recorded $790 million in revenue. The company’s MedSurg division saw $800 million in sales, according to an SEC filing. Most of the company&rsq...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Featured MassDevice Earnings Roundup Wall Street Beat Alphatec Boston Scientific Hologic ICON plc Integra LifeSciences NovoCure Orthofix SeaSpine Source Type: news
The National Cancer Institute in Rockville, Maryland, has opened an innovative clinical trial for patients with peritoneal mesothelioma that will explore the safety and effectiveness of a novel CAR T-cell therapy. The phase I trial also is being conducted at Washington University in St. Louis. It is aimed at patients whose disease has relapsed after initial chemotherapy treatment. It involves a laboratory modification of a patient’s T cells — a type of white blood cell — that can help the immune system kill the cancer. CAR T-cell therapy is a form of gene therapy that has been highly successful with blood...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Standard-of-care treatment for patients with pleural mesothelioma may soon include Tumor Treating Fields (TTF), a novel therapy involving electric currents that disrupt cancer cell division and inhibit tumor growth. In the wake of recently released results from Novocure’s STELLAR phase II clinical trial, the U.S. Food and Drug Administration (FDA) is expected to approve the treatment within the next six months, giving mesothelioma patients another much-needed option. “At this point, it should be a relatively rapid approval process,” Dr. Eilon Kirson, chief science officer at Novocure, the oncology company...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Oncologists in 2019 may begin offering patients with pleural mesothelioma a novel, tumor-fighting tool involving electric currents that enhance standard-of-care treatment and extend survival, according to the device manufacturer. Tumor Treating Fields (TTF) is the name of the new technology. It is designed to disrupt cancer cell division through electric fields tuned to specific frequencies. In an ongoing multicenter phase II clinical trial in Europe, TTF has shown an ability in first-line treatment to improve the effectiveness of standard chemotherapy for mesothelioma patients. The trial success has led the manufacturer t...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
The National Cancer Institute,Laboratory of Molecular Biologyseeks parties interested in collaborative research to further co-develop monoclonal antibodies for the treatment of mesothelin-expressing cancers. The antibody was able to inhibit tumor growth in mouse xenograft models, and corresponding immunotoxins were able to inhibit tumor cell growth in vitroMesothelin is a cell surface protein that is highly expressed in aggressive cancers such as malignant mesothelioma, ovarian cancer, pancreatic cancer, lung cancer, breast cancer, cholangiocarcinoma, bile duct carcinoma and gastric cancer. This selective expression makes ...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
Shares in Novocure (NSDQ:NVCR) are on the rise today after the medical device maker topped revenue and losses-per-share expectations on Wall Street with its 3rd quarter earnings results. The St. Helier, N.J.-based company posted losses of $11.5 million, or 13¢ per share, on sales of $50.1 million for the 3 months ended September 30, seeing losses on the bottom-line shrink 65.8% while sales grew 131.2% compared with the same period during the previous fiscal year. Losses per share for the quarter came in under the 17¢ consensus on Wall Street, while sales beat the $43.6 million expectations on The Street. &ld...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News MassDevice Earnings Roundup NovoCure Source Type: news
Isabel De La Camara has forgotten about the mesothelioma cancer brewing inside her belly. Her concern for others — and her desire to help them — has overshadowed everything else in her life today. De La Camara, who lives in Central Florida, has hardly slept since Hurricane Maria ripped through her beloved Puerto Rico last week, carving a horrific path of destruction that left more than 3 million people without adequate food, water and other basic necessities. Some of her closest friends and family members are among those hit the hardest in San Juan, where she was born and raised, and one day — hopefully ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: Change Your Community Christian Sharing Center cytoreduction surgery Hurricane Maria Hurricane Maria asbestos Isabel De La Camara mesothelioma treatment peritoneal mesothelioma Puerto Rico Puerto Rico asbestos exposure Puerto Rico care Source Type: news
Pleural and peritoneal mesothelioma patients are eligible for a new clinical trial that combines the latest antibody-drug conjugate with standard-of-care chemotherapy at the Ochsner Medical Center in New Orleans. The drug, anetumab ravtansine (BAY 94-9343), is the highly touted conjugate that mixes immunotherapy with cytotoxic therapy and targets mesothelin, the tumor surface protein found in 85-90 percent of mesothelioma cancer patients. The Ochsner trial, which is currently recruiting participants, is the first time researchers will administer anetumab ravtansine in a first-line setting for mesothelioma. “It’...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: anetumab ravtansine mesothelioma chemotherapy mesothelioma clinical trial new mesothelioma treatment ochsner clinical trial Source Type: news
NovoCure (NSDQ:NVCR) today released results from the ongoing phase 2 pilot clinical trial of its Optune device combined with chemotherapy for patients with unresectable, previously untreated mesothelioma. Data from the trial is also slated to be presented at the International Association for the Study of Lung Cancer’s 17th World Conference on Lung Cancer on December 7. The St. Helier, N.J.-based company’s Optune is a mobile device that delivers low-intensity, intermediate frequency, alternating electric fields, referred to as “tumor treating fields” to inhibit cancer cell replication and c...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Clinical Trials Oncology NovoCure Source Type: news
In this study, the role of MSLN in the carcinogenic transformation of human bronchial epithelial cells chronically exposed to single-walled CNT (BSW) was investigated. MSLN overexpression was found in human lung tumors, lung cancer cell lines, and BSW cells. The functional role of MSLN in the BSW cells was then investigated by using stably transfected MSLN knockdown (BSW shMSLN) cells. MSLN knockdown resulted in significantly decreased invasion, migration, colonies on soft agar, and tumor sphere formation. In vivo, BSW shMSLN cells formed smaller primary tumors and less metastases. The mechanism by which MSLN contributes t...
Source: AJP: Lung Cellular and Molecular Physiology - Category: Respiratory Medicine Authors: Tags: CALL FOR PAPERS Source Type: research
More News: Allergy & Immunology | Asbestosis | Bone Marrow Transplant | Cancer | Cancer & Oncology | Cancer Therapy | Cancer Vaccines | Chemotherapy | Clinical Trials | Environmental Health | Food and Drug Administration (FDA) | Georgia Health | Grants | Harvard | Hospitals | Immunotherapy | Liver | Liver Transplant | Lung Cancer | Lung Transplant | Mesothelioma | Ovarian Cancer | Ovaries | Pancreas | Pancreatic Cancer | Science | Stem Cell Therapy | Stem Cells | Study | Transplants | Urology & Nephrology | Vaccines | Veterinary Vaccinations